We have license agreements with Bausch and Lomb for both the Vitrasert product and the Retisert product. We also have a license agreement with Alimera for ocular applications of the ILUVIEN device. We have a collaboration agreement with Pfizer for the Durasert device delivering latanoprost.
We have 2 FDA approved products, Vitrasert and Retisert. Both are being sold by Bausch and Lomb. ILUVIEN received a positive outcome from the EU Decentralized Procedure and has subsequently received formal marketing authorization in the U.K., Austria, France, Germany, Portugal, Spain,Italy, Norway and Denmark.